US Edition
VytlOne Announces New Partnership with Insmed
Brinsupri reduces lung exacerbations by over 19% and slows lung function decline, addressing an unmet need for nearly 500,000 U.S. patients with non-cystic fibrosis bronchiectasis.
- On August 12, 2025, Insmed received FDA authorization to market brensocatib as a treatment option for both adults and adolescents with non-cystic fibrosis bronchiectasis in the United States.
- This approval followed positive Phase 3 trial results showing brensocatib reduced pulmonary exacerbations and slowed lung function decline in a disease with no prior treatments.
- Brensocatib is a first-in-class DPP1 inhibitor and is distributed through Maxor Specialty Pharmacy, which will rebrand as VytlOne Specialty Pharmacy in 2026 for comprehensive rare disease support.
- Insmed's market capitalization nearly reached $26 billion on the approval day, with Wall Street analysts projecting up to $6 billion annual sales for Brinsupri and limited safety restrictions noted.
- The approval offers a new standard treatment option for approximately 500,000 U.S. patients and millions globally, though risks remain in commercialization, regulatory, and market acceptance.
27 Articles
27 Articles
Farm Talk Newspaper
VytlOne Announces New Partnership with Insmed
AMARILLO, Texas, Aug. 13, 2025 /PRNewswire/ -- Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis…
The first oral medicine for a rare lung disease, approved in the United States. The administration of Food and Medicines (FDA) in the United States gave one green first oral therapy for non-Chistic fibrosis (NCSB), a rare pulmonary infection that can affect both adults and adolescents over 12 years of age. The first oral medicine for [...]
FDA Approval of First-in-Class BRINSUPRI Offers New Hope for Hundreds of Thousands with Chronic Lung Disease
The U.S. Food and Drug Administration (FDA) has approved Insmed’s oral drug BRINSUPRI (brensocatib) as the first treatment for non-cystic fibrosis bronchiectasis (NCFB) in patients … FDA Approval of First-in-Class BRINSUPRI Offers New Hope for Hundreds of Thousands with Chronic Lung Disease Read More » The post FDA Approval of First-in-Class BRINSUPRI Offers New Hope for Hundreds of Thousands with Chronic Lung Disease first appeared on GeneOnlin…
Serious Chronic Lung Disease Gets First FDA-Approved Drug
(MedPage Today) — The FDA approved oral brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis in adults and kids 12 years and up, drugmaker Insmed announced on Tuesday. A first-in-class reversible dipeptidyl peptidase… Source link : https://www.medpagetoday.com/pulmonology/generalpulmonary/116965 Author : Publish date : 2025-08-12 21:10:00 Copyright for syndicated content belongs to the linked Source. The post Ser…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
